✦ LIBER ✦

Phosphodiesterase type 5 inhibitors and nitrates: Is concomitant use safe? Are there alternatives?

✍ Scribed by Nachum M. Katlowitz; Angelo DeRosalio

Book ID: 107554448
Publisher: Springer
Year: 2007
Tongue: English
Weight: 110 KB
Volume: 4
Category: Article
ISSN: 1548-3584
DOI: 10.1007/s11930-007-0003-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phosphodiesterase type 5 inhibitors, vis

Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: Is there a link?

✍ Konstantinos Hatzimouratidis 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 278 KB

Is there a rationale for the chronic use

Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?

✍ Thierry Roumeguère; K. Zouaoui Boudjeltia; Claude Hauzeur; Claude Schulman; Mich 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB

1253 A SYSTEMATIC REVIEW AND META-ANALYS

1253 A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE USE OF PHOSPHODIESTERASE TYPE 5 INHIBITORS (PDE5-IS) FOR LOWER URINARY TRACT SYMPTOMS (LUTS) SECONDARY TO BENIGN PROSTATIC HYPERPLASIA (BPH)

✍ Gacci, Mauro; Corona, Giovanni; Salvi, Matteo; Vignozzi, Linda; McVary, Kevin T. 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 112 KB

644 Systematic review and meta-analysis

644 Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors (pde5-is) alone or in combination with alpha blockers for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)

✍ M. Gacci; G. Corona; M. Salvi; L. Vignozzi; K.T. McVary; S.A. Kaplan; C.G. Roehr 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 17 KB

MAGNA CARTAThe Great CharterPreamble

📂 Fiction 🌐 English ⚖ 11 KB 👁 18 views